One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan-Reference-Cited by-同舟云学术

One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan

Published:2023-06 Issue:29 Volume:41 Page:4199-4205
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Ishikawa Kensuke,Nascimento Maria-Claudia,Asano Michiko,Hirata Hajime,Itoh Yohji,Kelly Elizabeth J.,Matsui Akiko,Olsson Urban,Shoemaker Kathryn,Green Justin

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference18 articles.

1. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months;Levin;N Engl J Med,2021

2. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant;Andrews;N Engl J Med,2022

3. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19;Doria-Rose;N Engl J Med,2021

4. COVID-19 vaccine booster: To boost or not to boost;Shekhar;Infect Dis Rep,2021

5. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study;Watson;Lancet Infect Dis,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study;Vaccines;2024-08-03

2. Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein;npj Vaccines;2024-06-03

3. A fatal course of COVID-19 during the Omicron surge: can you estimate your patients’ SARS-CoV-2 immune status?;Infection;2023-11-06